{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:07:13Z","timestamp":1788934033448,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the temporal association between voriconazole and hypomagnesemia in pediatric patients with hematologic diseases using prescription sequence symmetry analysis (PSSA) and to assess the utility of hospital information system (HIS)-based active drug safety surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Inpatient data were extracted from the Children\u2019s Hospital of Chongqing Medical University from November 2013 to December 2024. The first year served as a data integrity verification window and the subsequent approximately 10-year period as the formal analysis phase. Patients with hematologic diseases were identified using ICD-10 codes C81\u2013C96, D45\u2013D47, and D60\u2013D61. Each patient contributed the first voriconazole prescription and first hypomagnesemia event (Mg\n                      <jats:sup>2+<\/jats:sup>\n                      &amp;lt; 0.6\u00a0mmol\/L). The primary analysis used a 365-day washout period, 90-day exposure window, and 7-day blackout period. Adjusted sequence ratios (aSRs) with 95% confidence intervals (CIs) were estimated, with 10 parameter sensitivity analyses, monitoring-intensity correction, four control analyses, and stratified analyses by concomitant medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 536 eligible patients, 364 (67.9%) had serum magnesium measurements. The post-exposure sequence comprised 58 patients and the reverse sequence eight patients, yielding an aSR of 5.76 (95% CI: 2.75\u201312.06). Median time to hypomagnesemia after voriconazole initiation was 28 days (IQR: 20\u201343), and 32\/58 events (55.2%) occurred within 30 days. Exploratory dose-response analysis showed no association between weight-based voriconazole dose and hypomagnesemia occurrence (P = 0.437). All parameter sensitivity analyses produced aSRs &amp;gt;3.9; after correction for monitoring intensity, the aSR was 3.33 (95% CI: 1.59\u20136.98); in a sensitivity grid, the association remained statistically significant for monitoring-intensity ratios up to 2.75. All four control analyses agreed with their prespecified expectations. Associations remained significant in the PPI and aminoglycoside strata, whereas the loop-diuretic non-user stratum showed the same direction but was not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Voriconazole initiation was temporally associated with subsequent hypomagnesemia in pediatric patients with hematologic diseases. PSSA may complement spontaneous reporting systems for detecting laboratory-defined safety signals. Weekly serum magnesium monitoring should be considered during the first 30 days of voriconazole therapy. These findings support a temporal association but do not establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1948603","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:49:06Z","timestamp":1788932946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription sequence symmetry analysis of voriconazole-associated hypomagnesemia in pediatric patients with hematologic diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Intelligent Application of Big Data in Pediatrics Engineering Research Center of Chongqing Education Commission of China","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Intelligent Application of Big Data in Pediatrics Engineering Research Center of Chongqing Education Commission of China","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbo","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Intelligent Application of Big Data in Pediatrics Engineering Research Center of Chongqing Education Commission of China","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00298.2022","article-title":"Magnesium reabsorption in the kidney","volume":"324","author":"de Baaij","year":"2023","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00012.2014","article-title":"Magnesium in man: implications for health and disease","volume":"95","author":"de Baaij","year":"2015","journal-title":"Physiol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12874-016-0278-0","article-title":"Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review","volume":"17","author":"Gault","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/bcp.70556","article-title":"Therapeutic drug monitoring of antimicrobials in a paediatric setting: a retrospective single-centre study","volume":"92","author":"Gazzaniga","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e13846","DOI":"10.1111\/apha.13846","article-title":"Mechanisms of proton pump inhibitor-induced hypomagnesemia","volume":"235","author":"Gommers","year":"2022","journal-title":"Acta Physiol. (Oxf)"},{"key":"B7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00001648-199609000-00005","article-title":"Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis","volume":"7","author":"Hallas","year":"1996","journal-title":"Epidemiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12874-023-02108-y","article-title":"Prescription sequence symmetry analysis (PSSA) to assess prescribing cascades: a step-by-step guide","volume":"24","author":"Hendrix","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc. R. Soc. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/pbc.24460","article-title":"Magnesium homeostasis and hypomagnesemia in children with malignancy","volume":"60","author":"Kaplinsky","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40264-020-00940-5","article-title":"Detecting medicine safety signals using prescription sequence symmetry analysis of a national prescribing data set","volume":"43","author":"King","year":"2020","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1524702","DOI":"10.3389\/fphar.2025.1524702","article-title":"Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/01.ASN.0000113318.56023.B6","article-title":"Downregulation of Ca2+ and Mg2+ transport proteins in the kidney explains tacrolimus (FK506)-Induced hypercalciuria and hypomagnesemia","volume":"15","author":"Nijenhuis","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.3780","article-title":"Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries","volume":"24","author":"Pratt","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3390\/pharmaceutics13121991","article-title":"Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies","volume":"13","author":"Resztak","year":"2021","journal-title":"Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.mayocp.2022.12.002","article-title":"Acquired disorders of hypomagnesemia","volume":"98","author":"Rosner","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1053\/j.gastro.2009.12.052","article-title":"SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease","volume":"138","author":"Schwimmer","year":"2010","journal-title":"Gastroenterology"},{"key":"B22","volume-title":"VFEND (Voriconazole) Prescribing Information","year":"2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/pds.5293","article-title":"Use of negative controls in a prescription sequence symmetry analysis to reduce time-varying bias","volume":"30","author":"Vouri","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","article-title":"The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection","volume":"22","author":"Wahab","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1684\/mrh.2025.0546","article-title":"Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA adverse event reporting system","volume":"38","author":"Xiao","year":"2024","journal-title":"Magnes. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1948603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:49:13Z","timestamp":1788932953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1948603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1948603"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1948603","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1948603"}}